Thursday, October 22, 2020

ADMA Biologics Inc. [ADMA] stock Initiated by Jefferies analyst, price target now $8

Must read

For Altria Group Inc. [MO], Barclays sees a rise to $43. What next?

Altria Group Inc. stock went on an upward path that rose over 0.38% on Thursday, amounting to a one-week price decrease of less...

UBS lifts International Business Machines Corporation [IBM] price estimate. Who else is bullish?

International Business Machines Corporation plunged by -$1.05 during the normal trading session on Thursday and reaching a high of $125.215 during the day...

Empire State Realty Trust Inc. [ESRT] Revenue clocked in at $699.10 million, down -53.51% YTD: What’s Next?

Empire State Realty Trust Inc. closed the trading session at $6.49 on 10/16/20. The day’s price range saw the stock hit a low...

Equity Residential [EQR] Revenue clocked in at $2.70 billion, down -37.33% YTD: What’s Next?

Equity Residential slipped around -1.14 points on Monday, while shares priced at $50.71 at the close of the session, down -2.20%. The company...

ADMA Biologics Inc. [NASDAQ: ADMA] loss -3.77% or -0.08 points to close at $2.04 with a heavy trading volume of 2530870 shares.

It opened the trading session at $2.06, the shares rose to $2.11 and dropped to $1.98, the range by which the price of stock traded the whole day. The daily chart for ADMA points out that the company has recorded -34.41% loss over the past six months. However, it is still -40.69% lower than its most recent low trading price.

If we look at the average trading volume of 5.98M shares, ADMA reached to a volume of 2530870 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about ADMA Biologics Inc. [ADMA]:

Jefferies have made an estimate for ADMA Biologics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 04, 2019. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $10 to $13. The new note on the price target was released on April 15, 2019, representing the official price target for ADMA Biologics Inc. stock. Previously, the target price had yet another raise to $10, while H.C. Wainwright analysts kept a Buy rating on ADMA stock. On December 11, 2017, analysts decreased their price target for ADMA shares from 13 to 8.

The Average True Range (ATR) for ADMA Biologics Inc. is set at 0.20, with the Price to Sales ratio for ADMA stock in the period of the last 12 months amounting to 4.80. The Price to Book ratio for the last quarter was 2.29, with the Price to Cash per share for the same quarter was set at 0.87.

Trading performance analysis for ADMA stock

ADMA Biologics Inc. [ADMA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.35. With this latest performance, ADMA shares dropped by -27.92% in over the last four-week period, additionally sinking by -34.41% over the last 6 months – not to mention a drop of -57.59% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADMA stock in for the last two-week period is set at 34.91, with the RSI for the last a single of trading hit 25.94, and the three-weeks RSI is set at 36.03 for ADMA Biologics Inc. [ADMA]. The present Moving Average for the last 50 days of trading for this stock 2.76, while it was recorded at 2.21 for the last single week of trading, and 3.12 for the last 200 days.

ADMA Biologics Inc. [ADMA]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and ADMA Biologics Inc. [ADMA] shares currently have an operating margin of -141.14 and a Gross Margin at -37.48. ADMA Biologics Inc.’s Net Margin is presently recorded at -164.50.

Return on Total Capital for ADMA is now -47.36, given the latest momentum, and Return on Invested Capital for the company is -55.28. Return on Equity for this stock declined to -210.08, with Return on Assets sitting at -44.71. When it comes to the capital structure of this company, ADMA Biologics Inc. [ADMA] has a Total Debt to Total Equity ratio set at 323.48. Additionally, ADMA Total Debt to Total Capital is recorded at 76.39, with Total Debt to Total Assets ending up at 66.67. Long-Term Debt to Equity for the company is recorded at 322.61, with the Long-Term Debt to Total Capital now at 76.18.

Reflecting on the efficiency of the workforce at the company, ADMA Biologics Inc. [ADMA] managed to generate an average of -$153,756 per employee. Receivables Turnover for the company is 12.07 with a Total Asset Turnover recorded at a value of 0.27.ADMA Biologics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.80 and a Current Ratio set at 11.10.

ADMA Biologics Inc. [ADMA]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, ADMA Biologics Inc. posted -0.19/share EPS, while the average EPS was predicted by analysts to be reported at -0.23/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 17.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADMA.

An analysis of insider ownership at ADMA Biologics Inc. [ADMA]

There are presently around $108 million, or 62.90% of ADMA stock, in the hands of institutional investors. The top three institutional holders of ADMA stocks are: PERCEPTIVE ADVISORS LLC with ownership of 16,584,802, which is approximately 0% of the company’s market cap and around 0.70% of the total institutional ownership; BLACKROCK INC., holding 5,721,937 shares of the stock with an approximate value of $11.67 million in ADMA stocks shares; and AISLING CAPITAL LLC, currently with $7.36 million in ADMA stock with ownership of nearly 0% of the company’s market capitalization.

Positions in ADMA Biologics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 53 institutional holders increased their position in ADMA Biologics Inc. [NASDAQ:ADMA] by around 4,704,672 shares. Additionally, 43 investors decreased positions by around 4,281,960 shares, while 17 investors held positions by with 44,004,467 shares. The mentioned changes placed institutional holdings at 52,991,099 shares, according to the latest SEC report filing. ADMA stock had 20 new institutional investments in for a total of 2,020,690 shares, while 17 institutional investors sold positions of 2,110,032 shares during the same period.

More articles


Please enter your comment!
Please enter your name here

Latest article

Titan Pharmaceuticals Inc. [TTNP] is -39.31% lower this YTD. Is it still time to buy?

Titan Pharmaceuticals Inc. slipped around -0.02 points on Tuesday, while shares priced at $0.12 at the close of the session, down -14.33%. The...

For Tyson Foods Inc. [TSN], Credit Suisse sees a drop to $68. What next?

Tyson Foods Inc. stock went on a downward path that fall over -0.77% on Tuesday, amounting to a one-week price decrease of less...

Market Analysts see Alliance Data Systems Corporation [ADS] gaining to $67. Time to buy?

Alliance Data Systems Corporation loss -4.55% on the last trading session, reaching $51.76 price per share at the time. The company report on...

Robert Half International Inc. [RHI] Revenue clocked in at $5.70 billion, down -10.85% YTD: What’s Next?

Robert Half International Inc. surged by $0.87 during the normal trading session on Tuesday and reaching a high of $57.31 during the day...

Foot Locker Inc. [FL] Is Currently 1.35 below its 200 Period Moving Avg: What Dose This Mean?

Foot Locker Inc. traded at a high on 10/20/20, posting a 1.35 gain after which it closed the day’ session at $38.37. The...